Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 3
2005 1
2006 2
2007 6
2008 11
2009 9
2010 6
2011 2
2012 7
2013 6
2014 4
2015 12
2016 16
2017 21
2018 26
2019 20
2020 25
2021 20
2022 15
2023 15
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Results by year

Filters applied: . Clear all
Page 1
Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis.
Illini O, Saalfeld FC, Christopoulos P, Duruisseaux M, Vikström A, Peled N, Demedts I, Dudnik E, Eisert A, Hashemi SMS, Janzic U, Kian W, Mohorcic K, Mohammed S, Silvoniemi M, Rothschild SI, Schulz C, Wesseler C, Addeo A, Armster K, Itchins M, Ivanović M, Kauffmann-Guerrero D, Koivunen J, Kuon J, Pavlakis N, Piet B, Sebastian M, Velthaus-Rusik JL, Wannesson L, Wiesweg M, Wurm R, Albers-Leischner C, Aust DE, Janning M, Fabikan H, Herold S, Klimova A, Loges S, Sharapova Y, Schütz M, Weinlinger C, Valipour A, Overbeck TR, Griesinger F, Jakopovic M, Hochmair MJ, Wermke M. Illini O, et al. Among authors: peled n. Int J Mol Sci. 2024 Apr 3;25(7):3992. doi: 10.3390/ijms25073992. Int J Mol Sci. 2024. PMID: 38612799 Free PMC article.
Personalizing non-small cell lung cancer treatment through patient-derived xenograft models: preclinical and clinical factors for consideration.
Fuchs V, Sobarzo A, Msamra M, Kezerle Y, Linde L, Sevillya G, Anoze A, Refaely Y, Cohen AY, Melamed I, Azriel A, Shoukrun R, Raviv Y, Porgador A, Peled N, Roisman LC. Fuchs V, et al. Among authors: peled n. Clin Transl Oncol. 2024 Mar 29. doi: 10.1007/s12094-024-03450-3. Online ahead of print. Clin Transl Oncol. 2024. PMID: 38553659
In Response.
Nisman B, Oleinikov K, Nechushtan H, Maimon O, Atlan K, Peled N, Gross D, Peretz T, Meirovitz A, Grozinsky-Glasberg S. Nisman B, et al. Among authors: peled n. J Thorac Oncol. 2023 Nov;18(11):e139-e141. doi: 10.1016/j.jtho.2023.08.032. J Thorac Oncol. 2023. PMID: 37879775 No abstract available.
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourão Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators. Zhou C, et al. N Engl J Med. 2023 Nov 30;389(22):2039-2051. doi: 10.1056/NEJMoa2306441. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870976 Clinical Trial.
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K; LIBRETTO-431 Trial Investigators. Zhou C, et al. N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870973 Clinical Trial.
BRCA mutations detected by tumour next-generation sequencing in non-small cell lung cancer: impact on response to therapy and disease course.
Tschernichovsky R, Averbuch I, Goldstein DA, Mutai R, Dudnik E, Rotem O, Laufer-Geva S, Peled N, Goldberg Y, Zer A. Tschernichovsky R, et al. Among authors: peled n. Transl Lung Cancer Res. 2023 May 31;12(5):1011-1022. doi: 10.21037/tlcr-22-594. Epub 2023 May 8. Transl Lung Cancer Res. 2023. PMID: 37323181 Free PMC article.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non-small cell lung cancer: A large real-world cohort and review of the literature.
Averbuch I, Tschernichovsky R, Icht O, Goldstein DA, Mutai R, Dudnik E, Rotem O, Peled N, Allen AM, Laufer-Geva S, Goldberg Y, Zer A. Averbuch I, et al. Among authors: peled n. Thorac Cancer. 2023 Jun;14(17):1589-1596. doi: 10.1111/1759-7714.14902. Epub 2023 Apr 24. Thorac Cancer. 2023. PMID: 37095004 Free PMC article. Review.
206 results